Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids

类固醇受体串扰与子宫肌瘤的发病机制

基本信息

  • 批准号:
    10618165
  • 负责人:
  • 金额:
    $ 35.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-02 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary Uterine fibroids (leiomyomoas) are the most common gynecologic tumor in women of reproductive age. Although these tumors are considered benign, they cause significant gynecologic and reproductive dysfunction. The molecular mechanisms that regulate the development and growth of uterine fibroids are not well-understood, which has resulted in limited, non-invasive therapeutic options. As such, uterine fibroids are the leading indication for hysterectomy in the United States. There is a critical need for new therapeutic interventions that involve selectively targeting the pathways that promote fibroid growth. We have recently discovered that activation of the glucocorticoid receptor (GR) promotes uterine fibroid cell proliferation. Moreover, we found that glucocorticoids induce a unique transcriptional response in uterine fibroid cells compared to normal myometrium. Studies in tumors of the breast and endometrium demonstrates that steroid hormone crosstalk allows context- specific signaling supporting tumor growth and is associated with a poor prognosis. Our preliminary data in the uterus indicates that GR demonstrates crosstalk with the sex hormone receptors, estrogen (ER) and progesterone (PR) receptor, known factors that induce uterine fibroid growth. A mechanistic understanding of glucocorticoid action in the uterus is limited, and thus, glucocorticoid signaling represents a previously unexplored pathway contributing to the pathogenesis of uterine fibroids. We hypothesize that GR functions as a critical transcriptional regulatory factor contributing to the pathogenesis of uterine fibroids. We propose to test our hypotheses in three specific aims. In Specific Aim 1, we will define the mechanisms responsible for the differential responses to glucocorticoids in uterine fibroids compared to normal myometrial cells. In Specific Aim 2, we will define the molecular mechanism by which GR regulates uterine fibroid cell proliferation. Finally, the goal of Aim 3 will be to discover how steroid hormone crosstalk regulates gene expression in uterine fibroid cells. The proposed work is innovative because our studies represent the first investigation into the actions of GR and the interplay of steroid hormone receptors in uterine fibroid cells. By defining the processes by which glucocorticoid signaling promotes fibroid cell proliferation, these studies will generate new data to advance our understanding of this highly prevalent gynecological disease. Successful completion of these studies may open the door to the development of interventions that selectively target GR regulatory factors or down-stream signaling molecules of GR for the non-invasive treatment of uterine fibroids.
项目摘要 子宫肌瘤(平滑肌瘤)是育龄妇女最常见的妇科肿瘤。虽然 这些肿瘤被认为是良性的,它们会引起严重的妇科和生殖功能障碍。的 调节子宫肌瘤的发展和生长的分子机制还不清楚, 这导致了有限的非侵入性治疗选择。因此,子宫肌瘤是 子宫切除术的病人迫切需要新的治疗干预措施, 选择性地靶向促进纤维瘤生长的途径。我们最近发现, 糖皮质激素受体(GR)促进子宫纤维瘤细胞增殖。此外,我们发现, 与正常子宫肌层相比,糖皮质激素在子宫纤维瘤细胞中诱导独特的转录应答。 对乳腺和子宫内膜肿瘤的研究表明,类固醇激素的相互作用使背景- 支持肿瘤生长的特异性信号传导,并与不良预后相关。我们的初步数据显示, 子宫表明GR表现出与性激素受体雌激素(ER)和 孕酮(PR)受体,已知的诱导子宫肌瘤生长的因子。机械地理解 糖皮质激素在子宫中的作用是有限的,因此,糖皮质激素信号传导代表了先前的 未探索的途径有助于子宫肌瘤的发病机制。我们假设GR的功能是 子宫肌瘤发病机制中的关键转录调控因子。我们建议测试 我们的假设有三个具体目标。在具体目标1中,我们将定义负责 与正常子宫肌层细胞相比,子宫肌瘤对糖皮质激素的反应不同。具体目标 2、明确GR调控子宫肌瘤细胞增殖的分子机制。最后 目的3的目标将是发现类固醇激素串扰如何调节子宫肌瘤细胞中的基因表达。 拟议的工作是创新的,因为我们的研究代表了第一次调查的行动, 子宫肌瘤细胞中类固醇激素受体的相互作用。通过定义 糖皮质激素信号促进纤维瘤细胞增殖,这些研究将产生新的数据,以推进我们的研究。 了解这种高度流行的妇科疾病。成功完成这些研究可能会打开 开发选择性靶向GR调节因子或下游的干预措施的大门 GR信号分子用于子宫肌瘤的非侵入性治疗。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Can We Treat Racism with Baby Aspirin?
我们可以用婴儿阿司匹林治疗种族主义吗?
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shannon D Whirledge其他文献

Shannon D Whirledge的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shannon D Whirledge', 18)}}的其他基金

Uterine Glucocorticoid Signaling: a Critical Pathway in the Establishment of Pregnancy
子宫糖皮质激素信号传导:妊娠建立的关键途径
  • 批准号:
    10561716
  • 财政年份:
    2021
  • 资助金额:
    $ 35.13万
  • 项目类别:
Uterine Glucocorticoid Signaling: a Critical Pathway in the Establishment of Pregnancy
子宫糖皮质激素信号传导:妊娠建立的关键途径
  • 批准号:
    10368918
  • 财政年份:
    2021
  • 资助金额:
    $ 35.13万
  • 项目类别:
Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids
类固醇受体串扰与子宫肌瘤的发病机制
  • 批准号:
    10227847
  • 财政年份:
    2020
  • 资助金额:
    $ 35.13万
  • 项目类别:
Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids
类固醇受体串扰与子宫肌瘤的发病机制
  • 批准号:
    10264278
  • 财政年份:
    2020
  • 资助金额:
    $ 35.13万
  • 项目类别:
Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids
类固醇受体串扰与子宫肌瘤的发病机制
  • 批准号:
    10391705
  • 财政年份:
    2020
  • 资助金额:
    $ 35.13万
  • 项目类别:
Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids
类固醇受体串扰与子宫肌瘤的发病机制
  • 批准号:
    10058465
  • 财政年份:
    2020
  • 资助金额:
    $ 35.13万
  • 项目类别:
Steroid Receptor Crosstalk and Pathogenesis of Uterine Fibroids
类固醇受体串扰与子宫肌瘤的发病机制
  • 批准号:
    10400080
  • 财政年份:
    2020
  • 资助金额:
    $ 35.13万
  • 项目类别:

相似海外基金

Genome analysis-based prediction model development for response to stereotactic radiosurgery in benign brain tumors
基于基因组分析的预测模型开发,用于良性脑肿瘤立体定向放射外科治疗的反应
  • 批准号:
    23K08495
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
Environmentally Benign Precise Transformations of Alkenes by Chiral Chalcogenide Catalysts
手性硫属化物催化剂对环境无害的烯烃精确转化
  • 批准号:
    22KJ2498
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Learners to LeAders in benign Urology, benign Nephrology, and non-Cancer Hematology
良性泌尿外科、良性肾脏病学和非癌症血液学领域的学习者和领导者
  • 批准号:
    10726042
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
  • 批准号:
    10607151
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
Development of a medical device to resolve benign esophageal stricture by heating and traction
开发通过加热和牵引解决良性食管狭窄的医疗设备
  • 批准号:
    23H03765
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of benign/malignant differentiation method for thyroid follicular tumor using organoids
利用类器官开发甲状腺滤泡性肿瘤良恶性鉴别方法
  • 批准号:
    23K08075
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis
p53在散发性肿瘤发生良性向恶性转变中的参与和作用机制
  • 批准号:
    10720034
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 35.13万
  • 项目类别:
    Standard Grant
Identifying the role of the gut microbiome in the etiology of benign breast disease
确定肠道微生物组在良性乳腺疾病病因学中的作用
  • 批准号:
    10359959
  • 财政年份:
    2022
  • 资助金额:
    $ 35.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了